News & Updates

Show Multimedia Only

EFS benefit greater with perioperative vs neoadjuvant-only nivolumab in resectable NSCLC

12 Nov 2024 by

Including adjuvant nivolumab as part of a perioperative regimen for resectable NSCLC further improves the EFS benefit vs including nivolumab in a neoadjuvant-only setting, as suggested by a patient-level data analysis of CheckMate 77T and CheckMate 816 investigating each modality separately

EFS benefit greater with perioperative vs neoadjuvant-only nivolumab in resectable NSCLC

12 Nov 2024

Aumolertinib ups PFS in EGFR-mutated NSCLC

08 Nov 2024 by

Treatment with aumolertinib significantly prolonged progression-free survival (PFS) compared with placebo in patients with unresectable stage III EGFR-mutated non-small cell lung cancer (NSCLC) who did not experience disease progression following chemoradiotherapy (CRT), according to a preplanned interim analysis of the phase III POLESTAR trial presented at WCLC 2024.

Aumolertinib ups PFS in EGFR-mutated NSCLC

08 Nov 2024

Original New Drug Application Approvals by US FDA (16-31 October 2024)

07 Nov 2024

New drug applications approved by US FDA as of 16-31 October 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 October 2024)

07 Nov 2024

Modified CXI predicts survival in CRC after surgery

06 Nov 2024 by

The modified cachexia index (mCXI) is effective in predicting the survival outcomes in patients with colorectal cancer (CRC) following radical surgery, reports a study.

Modified CXI predicts survival in CRC after surgery

06 Nov 2024

Is rapid-rate oxaliplatin safer than standard infusion?

06 Nov 2024

Rapid infusion of oxaliplatin appears to have minimal treatment modifications relative to standard administration but may lead to a higher incidence of peripheral neuropathy (PN), according to a study.

Is rapid-rate oxaliplatin safer than standard infusion?

06 Nov 2024

Pegaspargase biosimilar safe to use in childhood ALL

05 Nov 2024

The biosimilar Pegaspargase, when combined with chemotherapy, demonstrates a favourable safety profile in children with acute lymphoid leukemia (ALL) treated according to ICiCLe ALL-14 protocol, a study has shown.

Pegaspargase biosimilar safe to use in childhood ALL

05 Nov 2024

3 cycles of chemo enough for high-risk retinoblastoma in children

04 Nov 2024 by

Shortening the postenucleation chemotherapy regimen containing carboplatin, etoposide, and vincristine (CEV) from six to three cycles results in comparable survival outcomes in paediatric patients with unilateral pathologic high-risk retinoblastoma, according to new research.

3 cycles of chemo enough for high-risk retinoblastoma in children

04 Nov 2024

Tumour size, age predict survival in dermatofibrosarcoma protuberans

31 Oct 2024

The incidence of dermatofibrosarcoma protuberans (DFSP) is two times higher among Black than White individuals, reports a study.

Tumour size, age predict survival in dermatofibrosarcoma protuberans

31 Oct 2024

Healthy eating may hold back prostate cancer progression

26 Oct 2024 by

Sticking to a diet that follows the American dietary guideline recommendations may forestall the potential for low-grade prostate cancer to progress to high-grade disease, as suggested in a study.

Healthy eating may hold back prostate cancer progression

26 Oct 2024

Minimal access nipple-sparing mastectomy a viable breast cancer treatment option

26 Oct 2024

Minimal access nipple-sparing mastectomy compares favourably with conventional nipple-sparing mastectomy, with similar complication rates indicating that the two approaches are equally safe, according to a study.

Minimal access nipple-sparing mastectomy a viable breast cancer treatment option

26 Oct 2024

News & Updates

Filter by Specialty:

Specialty:

EFS benefit greater with perioperative vs neoadjuvant-only nivolumab in resectable NSCLC

EFS benefit greater with perioperative vs neoadjuvant-only nivolumab in resectable NSCLC

Aumolertinib ups PFS in EGFR-mutated NSCLC

Aumolertinib ups PFS in EGFR-mutated NSCLC

Original New Drug Application Approvals by US FDA (16-31 October 2024)

Original New Drug Application Approvals by US FDA (16-31 October 2024)

Modified CXI predicts survival in CRC after surgery

Modified CXI predicts survival in CRC after surgery

Is rapid-rate oxaliplatin safer than standard infusion?

Is rapid-rate oxaliplatin safer than standard infusion?

Pegaspargase biosimilar safe to use in childhood ALL

Pegaspargase biosimilar safe to use in childhood ALL

3 cycles of chemo enough for high-risk retinoblastoma in children

3 cycles of chemo enough for high-risk retinoblastoma in children

Tumour size, age predict survival in dermatofibrosarcoma protuberans

Tumour size, age predict survival in dermatofibrosarcoma protuberans

Healthy eating may hold back prostate cancer progression

Healthy eating may hold back prostate cancer progression

Minimal access nipple-sparing mastectomy a viable breast cancer treatment option

Minimal access nipple-sparing mastectomy a viable breast cancer treatment option